Wire · opportunities
FDA Action Update, August 2026: Approvals, Clearances, and Designations
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
In August 2026, the FDA approved the first oral orexin receptor 2 agonist Oveporexton for narcolepsy type 1, cleared a phase 2 trial for Quantum BioPharma's demyelination-targeting Lucid-MS in progressive multiple sclerosis, and approved the tau PET tracer Tauklarify for Alzheimer's diagnostic imaging.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You must pivot quickly to integrate orexin-driven therapies and advanced diagnostic tools into your neurology portfolio as FDA approvals now open new treatment and diagnostic channels in narcolepsy and Alzheimer’s. This opens doors to reshape clinical strategies around earlier intervention and symptom targeting.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics